Opaleye Management’s Protagonist Therapeutics PTGX Stock Holding History

Opaleye Management’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$12.3M	Hold	100,000	–	–	1.11%	25
2026 Q1	$10.5M	Sell	100,000 -5,000	-5%	-$443K	1.39%	21
2025 Q4	$9.17M	Hold	105,000	–	–	1.21%	20
2025 Q3	$6.98M	Hold	105,000	–	–	0.99%	23
2025 Q2	$5.8M	Hold	105,000	–	–	1.17%	21
2025 Q1	$5.08M	Hold	105,000	–	–	1.13%	16
2024 Q4	$4.05M	Hold	105,000	–	–	0.71%	27
2024 Q3	$4.72M	Hold	105,000	–	–	0.79%	25
2024 Q2	$3.64M	Sell	105,000 -7,700	-7%	-$226K	0.83%	33
2024 Q1	$3.26M	Hold	112,700	–	–	0.71%	34
2023 Q4	$2.58M	Buy	+112,700	New	+$1.97M	0.69%	36
2022 Q2	–	Sell	-251,500	Closed	-$5.96M	–	51
2022 Q1	$5.96M	Sell	251,500 -90,500	-26%	-$2.55M	1.85%	18
2021 Q4	$11.7M	Buy	342,000 +11,778	+4%	+$372K	2.48%	13
2021 Q3	$5.85M	Hold	330,222	–	–	1.09%	28
2021 Q2	$14.8M	Buy	330,222 +33,222	+11%	+$1.1M	2.46%	13
2021 Q1	$7.69M	Buy	297,000 +37,000	+14%	+$936K	1.13%	28
2020 Q4	$7.02M	Buy	+260,000	New	+$5.6M	0.92%	28

Other funds holding PTGX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Opaleye Management's PTGX Position: Q2 2026 in Review

Opaleye Management held its Protagonist Therapeutics (PTGX) position steady in Q2 2026 at 100,000 shares worth $12.3M. The position accounts for 1.11% of the portfolio, ranked #25.

Opaleye Management first reported a position in PTGX in Q4 2020 and has held it in 17 quarters since. The position peaked at $14.8M in Q2 2021. 343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

Opaleye Management held 100,000 shares of Protagonist Therapeutics worth $12.3M as of Q2 2026.
Opaleye Management left its Protagonist Therapeutics share count unchanged in Q2 2026.
Protagonist Therapeutics made up 1.11% of Opaleye Management's portfolio in Q2 2026, its #25 holding.
Opaleye Management first reported a position in Protagonist Therapeutics in Q4 2020 and has held it in 17 quarters since.
Opaleye Management's Protagonist Therapeutics position peaked at $14.8M in Q2 2021.
343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Opaleye Management's 13F filing for Q2 2026, filed 14 Aug 2026.